Division of Plastic Surgery, Mayo Clinic, Rochester, MN, USA.
Department of Surgery, Mayo Clinic, Jacksonville, FL, USA.
World J Surg Oncol. 2023 May 6;21(1):141. doi: 10.1186/s12957-023-03022-9.
Dermatofibrosarcoma protuberans (DFSP) of the breast is a dermal fibroblastic neoplasm requiring wide excisional margins due to recurrence rates ranging from 26 to 60%. The current literature on reconstructive options and utility of Mohs micrographic surgery for DFSP of the breast is scarce. We describe surgical management of DFSP of the breast at our institution with the largest case series reported to date.
A retrospective review was performed of women who underwent surgery for DFSP of the breast at our institution between 1990 and 2019. Continuous data was summarized using mean, median, and range; categorical data was summarized with frequency count and percentage. Preoperative lesion size and postoperative defect size were evaluated using 2-sided Fisher exact test, and p-values < 0.05 were considered statistically significant.
Nine patients underwent wide local excision (WLE) with reconstruction including pedicled latissimus dorsi flaps (n = 2), local flap advancement (n = 2), mastectomy with implant (n = 1), oncoplastic breast reduction (n = 1), and skin grafts (n = 3). Nine underwent Mohs micrographic surgery (MMS) with complex primary closure. Mean postoperative maximum wound defect size for WLE was 10.8 cm versus 7.0 cm for MMS with no statistical significance (p = 0.77). Mean preoperative maximum lesion size for WLE was 6.4 cm versus 3.3 cm for MMS with no statistical significance (p = 0.07). Complications with WLE included wound dehiscence in three patients and seroma in one patient. No complications were reported with MMS and primary closure. Recurrence was reported in one WLE patient, which was successfully detected despite flap coverage and resected without complications. Median follow-up for the patients without recurrence was 5.0 years, with two patients in MMS cohort lost to follow-up. Five-year overall survival was 100%.
MMS and WLE are both viable surgical options for managing DFSP of the breast. MMS could potentially minimize reconstructive needs due to smaller average defect size and result in fewer complications but may also result in asymmetry. Immediate flap reconstruction, especially in larger defects, can achieve excellent aesthetic outcomes for patients with DFSP of the breast without compromising detection of disease recurrence.
隆突性皮肤纤维肉瘤(DFSP)是一种真皮纤维母细胞瘤,由于复发率在 26%至 60%之间,因此需要广泛的切除边缘。目前关于乳房 DFSP 的重建选择和 Mohs 显微外科手术的应用的文献很少。我们描述了我们机构中乳房 DFSP 的手术治疗方法,这是迄今为止报告的最大病例系列。
对 1990 年至 2019 年在我们机构接受乳房 DFSP 手术的女性进行了回顾性研究。使用均值、中位数和范围总结连续数据;使用频率计数和百分比总结分类数据。使用双侧 Fisher 精确检验评估术前病变大小和术后缺损大小,p 值<0.05 认为具有统计学意义。
9 例患者行广泛局部切除术(WLE)加重建,包括带蒂背阔肌皮瓣(n=2)、局部皮瓣推进(n=2)、乳房切除术加植入物(n=1)、整形乳房缩小术(n=1)和皮片移植(n=3)。9 例行 Mohs 显微外科手术(MMS)加复杂一期闭合。WLE 的术后最大伤口缺损平均为 10.8cm,而 MMS 的平均为 7.0cm,无统计学意义(p=0.77)。WLE 的术前最大病变平均为 6.4cm,而 MMS 的平均为 3.3cm,无统计学意义(p=0.07)。WLE 并发症包括 3 例患者伤口裂开和 1 例患者血清肿。MMS 和一期闭合无并发症报告。1 例 WLE 患者复发,尽管有皮瓣覆盖,但仍成功发现并无并发症切除。无复发患者的中位随访时间为 5.0 年,2 例 MMS 患者失访。5 年总生存率为 100%。
MMS 和 WLE 都是治疗乳房 DFSP 的可行手术选择。MMS 由于平均缺损较小,可能减少重建需求,并且导致较少的并发症,但也可能导致不对称。对于乳房 DFSP 患者,立即进行皮瓣重建,特别是对于较大的缺损,可以实现极好的美学效果,而不会影响疾病复发的检测。